BCCI President Sourav Ganguly, who tested positive for COVID-19 late on Monday night, received monoclonal antibody cocktail therapy used to treat mild to moderate COVID-19 in high-risk patients. Woodlands Hospital, where Ganguly is admitted, issued a press statement that read: “He (Ganguly) received monoclonal antibody cocktail therapy the same night and is currently hemodynamically stable. In consultation with Dr Devi Shetty and Dr Aftab Khan A medical board comprising Dr Saroj Mandal, Dr Saptarshi Basu and Sautik Panda is keeping a close watch on his health condition.
Sourav Ganguly ‘stable’ after testing positive for Covid-19
Ganguly has been double vaccinated and is traveling extensively, participating in all professional activities. He was taken to the hospital late Monday night as a precautionary measure after the RT-PCR test of the 49-year-old came back positive. This is the third time this year that Sourav Ganguly has been admitted to the hospital. Earlier in January, he was taken to the hospital after complaining of chest pain. Doctors later said that he had suffered a heart attack while exercising at his Kolkata home and had undergone a right coronary angioplasty. A few weeks later, he felt similar chest pains, which led to the second round of angioplasty with two stents placed in two of his arteries.
BCCI President Sourav Ganguly hospitalized after testing positive for Covid-19: Report
What is monoclonal antibody cocktail therapy?
The antibody cocktail is a combination of two monoclonal antibodies: casirivimab and imdevimab. Both Imdevimab and Casirivimab are human immunoglobulin G-1 (IgG1) monoclonal antibodies that act against viruses. The antibody cocktail thwarts the attachment of the virus and its entry into the human cell. According to the Emergency Use Authorization (EUA), the cocktail antibody has the potential to treat mild to moderate COVID-19 infection in adults and patients over 12 years of age who are at high risk of developing severe disease and Do not need oxygen. Monoclonal antibodies are proteins that mimic the ability of our immune system to fight harmful pathogens such as viruses.
Monoclonal antibody cocktails may be given for the treatment of mild to moderate COVID-19 in adults and children over 12 years of age who are at high risk of severe COVID-19 infection and/or hospitalization. It is approved at a combined dose of 1200 mg (600 mg of each drug) administered by intravenous infusion or subcutaneous route
Indian pharmaceutical company Roche’s antibody cocktail is already being administered to COVID-19 patients with mild infections. Earlier this month, the drug also received emergency use approval from the Central Drugs Standard Control Organization (CDSCO), an India Today report said.
Roche’s antibody cocktail, being marketed in India by Cipla, is a combination of two drugs – casirivimab and imdevimab. Dr Naresh Trehan, a renowned cardiologist, has recommended its use in children above 40 kg. Cipla is marketing the drug in hospitals at an estimated cost of Rs 59,000 per dose. Only one dose is needed, the report says.
He said that rational use of antibody cocktail is important in the treatment of Kovid. It should be administered within three-ten days of the patient testing positive for COVID-19. Studies have shown that 80 percent of patients taking the drug did not require hospitalization.
The cocktail antibody was used during the treatment of former US President Donald Trump after he was tested positive for Covid-19 last year.
get all IPL news and cricket score Here
,